IP Library Patent Application 13130340
Patent Application
App. No. 13/130,340

METHOD FOR REDUCING THROMBOCYTOPENIA AND THROMBOCYTOPENIA-ASSOCIATED MORTALITY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/130,340
Abstract

Disclosed are methods for reducing the risk of thrombocytopenia-associated mortality and morbidity, and for reducing the risk of becoming thrombocytopenic, in patients whose treatment requires inhibition of platelet aggregation. The methods involve administration of a pharmaceutically acceptable salt of tirofiban.

Claims (9)

1 . A method for reducing the risk of thrombocytopenia-associated mortality which comprises administering to a patient suffering from a condition whose treatment requires the inhibition of platelet aggregation a therapeutically effective amount of a pharmaceutically acceptable salt of tirofiban.

2 . A method for reducing the risk of becoming thrombocytopenic which comprises administering to a patient suffering from a condition whose treatment requires the inhibition of platelet aggregation a therapeutically effective amount of a pharmaceutically acceptable salt of tirofiban.

3 . A method for reducing the risk of thrombocytopenia-associated morbidity which comprises administering to a patient suffering from a condition whose treatment requires the inhibition of platelet aggregation a therapeutically effective amount of a pharmaceutically acceptable salt of tirofiban.

4 . The method according to any one of claims 1 - 3 , wherein the tirofiban is administered intravenously as a high-dose bolus followed by a continuous infusion over time.

5 . The method according to claim 4 , wherein the high-dose bolus is about 25 μg/kg and the continuous infusion is about 0.15 μg/kg/min for about 18-24 hours.

6 . The method according to any one of claims 1 - 3 , wherein tirofiban hydrochloride is administered.

7 . The method according to claim 4 , wherein tirofiban hydrochloride is administered.

8 . The method according to claim 5 , wherein tirofiban hydrochloride is administered.

9 . The method according to claim 1 or 3 , wherein the patient is already thrombocytopenic; prethrombocytopenic or predisposed to thrombocytopenia; or normal in this regard.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2011
From: VALGIMIGLI, MARCO; PANTRADE INTERNATIONAL KFT
To: IROKO CARDIO LLC
Reel/Frame 026668/0500 →